Der blev jænvligt rapporteret om blødninger blandt patienter med UA/ NSTEMI og STEMI.
4.1% (enoxaparin) up to and including Day 9 in the Phase III UA/ NSTEMI study, and the incidence of adjudicated severe haemorrhage by modified TIMI criteria was 1.1% (fondaparinux) vs.